Industry / Canada

Biovail And Valeant Pharmaceuticals To Merge

June 2010 | Industry Trend Analysis

Printable version
Bookmark

BMI Core View: M&A activity will increase due to the efficiencies realised from

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Recalcine Expands Into Canada, Strengthens Position In Vietnam

Industry / Canada BMI Core View: Drugmakers based in emerging markets will expand their presence in developed countries. Firms in developing countries enjoy low operating costs but have historically lacked the capital to...

November 2011

Cost Concerns Impact National Reimbursement Strategy

Industry / Canada BMI View: While news that Canadian authorities have tightened public drug plans will come as no surprise, reimbursement trends favouring cost-effective studies over clinical success stories should hint...

October 2011

Drugmakers Buy Time With Piecemeal Monitoring System

Industry / Canada BMI View: While viewed as a positive first step, we do not believe a proposed drug monitoring system will let Canadian drugmakers off the hook from the government's ongoing calls for a concrete plan to...

October 2011

Industry Representatives Call For An Increase In Patent Protection

Industry / Canada BMI View: Innovation-based pharmaceutical companies require stable, predictable and internationally competitive intellectual property (IP) laws as well as a fast regulatory approval system to ensure their...

January 2011

Former Biovail CEO Quits Valeant

Industry / Canada BMI View: We believe there is a dichotomy in the strategies employed by pharmaceuticals companies. Traditionalists are refocusing on original research and development (R&D) and concentrating on their...

December 2010